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Abstract 
BACKGROUND: 
Middle East Respiratory Syndrome Coronavirus (MERS-CoV) infection emerged in 2012. The 
majority of cases occurred in the Kingdom of Saudi Arabia and the disease carries a high case 
fatality rate. 
METHODS: 
We present three MERS-CoV cases and highlight the salient clinical features and laboratory, 
and radiographic characteristics. 
RESULTS: 
Although all nasopharyngeal samples were negative, MERS CoV infection was confirmed by 
reverse transcription-polymerase chain reaction of the E gene (UpE) and open reading frame 
(ORF1b) on sputum samples. The Ct value of the ORF1 gene was 24.8-29.11. One patient had 
been on immune suppressive agent and two patients had diabetes mellitus. The average length 
of hospital stay was 10.6 days. Two patients received ribavirin and IFN-a2b in addition to 
supportive management. The clinical course for these patients started with a febrile period 
lasting five days, a reduction in fever was coinciding with increased respiratory rate and oxygen 
requirements. All patients were discharged home. None of the 50 contacts tested positive for 
MERS-CoV. 
CONCLUSION: 
Resolution of the fever was accompanied by an increase in oxygen requirements and 
respiratory rate also lasting several days. This was followed by resolution of all symptoms and 
return to normal. 
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Since the emergence of the Middle East Respiratory Syndrome-Coronavirus (MERS-CoV) infection in 
Saudi Arabia in 2012 [1], the World Health Organization (WHO) reported a total of 2090 cases including 
730 deaths [2].   Previous studies described clinical characteristics of MERS-CoV patients and the 
hospital outcome [3–6].   The utility of nasopharyngeal swabs and lower sputum samples were mentioned 
but were not clearly described.    In this paper, we describe three patients who had negative 
nasopharyngeal swabs but continued to have symptoms and sputum testing was confirmed the diagnosis 
of MERS-CoV.   MERS-CoV testing was done on either Dacron-flocked nasopharyngeal swabs or 
sputum samples and  were tested with real-time reverse-transcription polymerase chain reaction [7].   
The first case is a 56-year-old Saudi gentleman with erosive rheumatoid arthritis and had been on 
adalimumab and daily Prednisone (5 mg) was admitted with generalized tiredness, weakness, nausea, and 
dizziness.  He had no nausea, vomiting, or diarrhea.  The patient also described cough and sputum 
production.  He had no history of contact with animals.  He was awake, alert, and oriented to time, place, 
and person.  Maximum temperature was 37.5
0
C.  Oxygen saturation was 96% on 2 liters, blood pressure 
was 120/70 mm Hg, and respiratory rate was 18/minute.  Lung examination revealed vesicular breathing 
and end inspiratory crackles.  Chest x-ray revealed bilateral peripheral infiltrates and computerized axial 
tomography showed nonspecific bilateral patchy parenchymal airspace disease.  A nasopharyngeal swab 
was negative for both MERS-CoV and influenza by PCR and laboratory data are shown in table 1.  He 
was treated as a community acquired pneumonia.  Sputum test for MERS-CoV was positive.  He 
developed increasing oxygen requirements, and chest x-ray worsened despite broad spectrum antibiotics. 
He was gradually weaned off supplemental O2 therapy and was discharged home.   
The second case is a 52-year-old Saudi gentleman with history of diabetes mellitus and dyslipidemia was 
admitted with cough, sputum production and fever.  The patient has no nausea, vomiting or diarrhea.  The 
patient had no animal contact and no raw milk ingestion.  Vital signs were: temperature 38.5
0
C, blood 
pressure 120/70 mm Hg, and respiratory rate 18/minute.  There was no skin rash.  Lungs examination 
revealed decreased air entry at the basis with evidence of consolidation in the left lower zone posteriorly 
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with egophony.  A nasopharyngeal swab was negative for MERS-CoV and influenza by PCR.  Chest 
radiograph showed left lower lobe infiltrate and he was admitted.  He was treated as a community 
acquired pneumonia and then oseltimavir was added.  He continued to have fever of 38
0
C and developed 
faint skin rash that was thought maybe secondary to medication versus viral exanthem.  A repeat chest x-
ray showed progression of consolidation in the right upper lobe.  Five days after admission, his oxygen 
requirement started to increase (figure 1).  A sputum sample was positive for MERS-CoV by PCR.  He 
continued to have intermittent fever with increasing oxygen requirement.  He was started on interferon-
α2b and Ribavirin.   A repeat sample for MERS-CoV was negative from the nasopharyngeal however, 
and a sputum sample was positive for MERS-CoV (Table 1).  He required intensive care management and 
later he was discharged home. 
The third case is a 53-year-old Saudi gentleman with history of hepatitis B carrier, diabetes mellitus was 
admitted with six days history of cough productive of whitish sputum and fever.  He had mild nausea and 
vomiting, and loose bowel movement.  He had no contact with animal, no raw milk ingestion, and no 
history of travel.  Vital signs were: temperature of 39
0
C, O2 saturation 96% on room air, and respiratory 
rate was 16/minute.  He had a faint erythematous rash in the anterior upper chest area.  Lungs had 
vesicular breathing and end-inspiratory crackles in the right base posteriorly.  Nasopharyngeal swab for 
MERS-CoV was negative and a sputum sample was positive for MERS-CoV (table 1).  Chest x-ray 
showed patchy airspace disease in the right lower lobe and a CT scan revealed extensive patchy infiltrate.  
He was treated with interferon-α2b and ribavirin.  A repeat MERS testing was negative and the patient 
was discharged home. 
The three patients were febrile for about 5 days and then fever subsided (Figure 1).  The reduction in 
fever coincided with increased respiratory rate (figure 1) and increased inspiratory oxygen requirements.   
A total of 50 contracts tested negative based on nasopharyngeal swabs. 
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The three cases were confirmed MERS-CoV infection based on PCR testing of lower respiratory samples 
with Ct value <37  Initial case series indicated the value of nasopharyngeal swab testing for MERS-CoV 
diagnosis [7].  In two studies of the dynamics of MERS-CoV, lower respiratory samples showed higher 
Ct values and were detected later in the course of the disease [7,8].  The WHO recommends that both 
upper and lower respiratory tract specimens be collected whenever possible [9].  Thus, it is important to 
have repeat testing and lower respiratory samples in patients presenting with pneumonia to confirm or 
rule out MERS-CoV [8].  A total of 50 contracts tested negative based on nasopharyngeal swabs as 
recommended [9].  Variable contact results were cited in the different studies of 11–19% based on 
screening of 28–42 family contacts [10–12].  In a study of 462 family members, the positivity rate was 
3% by PCR [13]. Variable transmissions within healthcare settings were also cited.  An investigation of 
>200 healthcare workers showed two laboratory-confirmed cases [14].  In other settings, healthcare 
outbreaks were initiated by a single patient such as in Al-Hasa, Riyadh, Jeddah and South Korea [15,16].  
It was observed that patients were clinically stable with no tachypnea and then they had tachypnea and 
increased oxygen requirement by day 5-6.  Patients with MERS-CoV at the time of admission were less 
likely to have tachypnea (27%) compared to controls (60%), and less likely to have respiratory distress 
(15% vs. 51%) [3].  The timeline of the development of respiratory distress is within the reported time 
from onset to admission to intensive care unit and mechanical ventilation [17].  The exact mechanism for 
the development of respiratory distress coinciding with resolution of fever is interesting.  MERS infection 
appears to go through different phases.  Phase 1 is the phase of virologic replication and is characterized 
by fever and constitutional symptoms.  This is followed by phase 2 (immunopathological phase) 
characterized by resolution of fever and increased oxygen desaturation coupled with radiological 
deterioration.  Phase 3 is characterized by either further deterioration or resolution of symptoms as the 
case in these three patients.  There are no standard therapy for MERS-CoV and the use of interferon and 
ribavirin was suggested [18–20], however, there are no randomized controlled trials of anti-viral therapy.  
Two of the three cases in the present report were treated with interferon-α2b and ribavirin and all patients 
recovered.  The timing of the initiation of anti-viral agents seems to be important determinants of the 
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response to therapy.  The best time to initiate anti-viral agents is the phase of virologic replication before 
the development of immunopathological phase.  The first use of anti-viral in clinical setting was in a case 
series of five patients [18].  Therapy was initiated at a median time from admission to therapy of 19 
(range 10-22) days and none survived [18].  A subsequent study of 20 patients received ribavirin and 
interferon within a median of 3 days [range 0-8] after diagnosis [21].  The 14 day-survival rate was 70% 
of 20 patients in the treatment group compared with 29% of the comparator group (p=0·004) with no 
survival advantage at 28 days [21].  Thus, the use of interferon-α2b and ribavirin combination is a 
possible therapy and should be used early in the disease to have an impact. 
In conclusion, these three patients showed a three-phase illness characterized by initial phase of fever and 
clinical stability probably representing viral replication.  This phase was followed by a second phase of 
immunologic phase with clinical and radiographic deterioration and subsequent stabilization.  Treating 
physicians should be aware of the clinical course of the disease as well as the yield of respiratory samples 
in the detection of MERS-CoV. 
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Table 1: A Summary of the clinical, laboratory and radiographic manifestations of the reported 
MERS-CoV cases: 
 Case 1 Case 2 Case 3 
Age/Gender 56/M 52/M 53/M 
Days from onset to 
admission 
7 4 5  
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Comorbidities and 
medications 
Rheumatoid arthritis. 
Prednisone; 
Adalimumab 
Diabetes Mellitus; 
dyslipidemia 
Chronic HBV carrier, 
Diabetes Mellitus 
Animal Contacts No No No 
Nasopharyngeal Swap 1 Negative Negative Negative 
Nasopharyngeal Swap 2 Negative Negative  
Sputum 
UpE gene 
Orf 
Positive 
30.04 
27.9 
Positive 
29.03 
29.11 
Positive 
24.45 
24.8 
Nasopharyngeal Swap 3 Negative (5 days from 
first positive) 
Not done Not done 
Ribavarin and Interferon None Yes Yes 
Fever Yes Yes Yes 
Cough Yes Yes Yes 
GI symptoms Nausea None Nausea, vomiting, 
diarrhea 
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Initial CXR Bilateral peripheral 
infiltrate 
Consolidation right 
upper lobe 
Patchy air space disease 
right lower lobe 
Initial WBC 5100 1700 1800 
Hepatic Panel Elevated Normal Elevated 
Length of hospital stay 9 13 10 
 
Figure 1: A Scattered Graph Showing the Timeline Course of Temperature and Respiratory Rate 
by time from admission.  The Figure shows that resolution of fever by Day 6 coincided with 
increased respiratory rate.  
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